CASI Pharmaceuticals Inc
CASI
Company Profile
Business description
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Contact
No. 81, Jianguo Road
Room 1701-1702, China Central Office Tower 1
Huamao Office Building, Chaoyang District
Beijing100025
CHNT: +86 01065618789
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
233
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,290.50 | 86.60 | 1.06% |
| CAC 40 | 7,573.76 | 37.50 | 0.50% |
| DAX 40 | 22,271.67 | 29.22 | 0.13% |
| Dow JONES (US) | 40,227.59 | 114.09 | 0.28% |
| FTSE 100 | 8,417.34 | 2.09 | 0.02% |
| HKSE | 21,998.86 | 26.90 | 0.12% |
| NASDAQ | 17,366.13 | 16.81 | -0.10% |
| Nikkei 225 | 35,839.99 | 134.25 | 0.38% |
| NZX 50 Index | 12,062.47 | 36.42 | -0.30% |
| S&P 500 | 5,528.75 | 3.54 | 0.06% |
| S&P/ASX 200 | 8,075.50 | 78.40 | 0.98% |
| SSE Composite Index | 3,287.45 | 0.96 | -0.03% |